Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Project Oncology®Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Innovations in Bladder Monitoring for MS: Advancing Remote Evaluation Tools
NeuroFrontiersInnovations in Bladder Monitoring for MS: Advancing Remote Evaluation Tools
TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Prostate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
Clinician's RoundtableProstate Cancer and Cannabis Use: Exploring Results From a Case-Control Study
- advertisement
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CEExpert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
CME/CEAdvancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CEAntibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
- advertisement